BCL2 and pancreatic neoplasm: The effects of melatonin on pancreatic cancer cells could be related to the activation of melatonin membrane receptors (MT1/MT2), because pretreatment with luzindole (antagonist of these receptors) reversed the stimulatory effect of melatonin on Bcl-2/Bax balance and caspase-9 proteins expression in PANC-1 cells [43].